Amlodipine/atorvastatin: The first cross risk factor polypill for the prevention and treatment of cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 5, 2004, Pages 675-681

  Frishman, William H ^a   Zuckerman, Andrea L ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b PFIZER INC   (United States)

Author keywords

Adherence; Amlodipine; Atorvastatin; Cardiovascular disease; Dyslipidemia; Hypertension

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE PLUS ATORVASTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLESTEROL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; NICOTINIC ACID; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALSARTAN;

ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERTENSION; MYALGIA; NORTH AMERICA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RISK FACTOR; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TABLET FORMULATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DRUG COMBINATIONS; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES;

EID: 4544230271     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.5.675     Document Type: Article

References (35)

1. American Heart Association. Heart Disease and Stroke Statistits - 2004 Update. American Heart Associationm, TX, USA (2003).
2. US Department of Health and Human Services (DHHS), National Center for Health Statistics. Unpublished data from the third National Health And Nutrition Examination Survey (NHANES III Phase 2, 1991-1994). US Centers for Disease Control and Prevention (1994).
3. Rakugi H, Yu H, Kamitani A et al. Links between hypertension and myocardial infarction. Am. Heart J. 132, 213-221 (1996).
4. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am. J. Med. 80(2A), 33-39 (1986).
5. Samuelsson O, Wilhelmen L, Andersson OK et al. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, Sweden. J. Am. Med. Assoc. 258, 1768-1776 (1987).
6. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on detection, prevention, evaluation, and treatment of high blood pressure (the JNC 7 Report). J. Am. Med. Assoc. 289, 2560-2572 (2003).
7. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
8. Grundy SM, Cleeman JI, Bairey Merz CN et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
9. Schwartz JS, McLaughlin T, Griffis D, Arnold A, Pettitt D. Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both. J. Am. Coll. Cardiol. 41, 526A (2003) (Abstract).
10. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. 326, 1-6 (2003).
11. Jialal I, Stein D, Balis D et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103, 1933-1935 (2001).
12. Wassmann S, Laufs U, Baumer AT et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and rac1 GTPase. Mol. Pharmacol. 59, 646-654 (2001).
13. Wassmann S, Laufs U, Muller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22, 300-305 (2002).
14. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ. Res. 90, 737-44 (2002).
15. Sasaki S, Kuwahara N, Kunitomo K et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am. J. Cardiol. 89, 386-389 (2002).
16. Mancini GBJ. Antiatherosclerotic effects of calcium-channel blockers. Prog. Cardiovasc. Dis. 45, 1-20 (2002).
17. Zhang X-P, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J. Cardiovasc. Pharmacol. 35, 195-202 (2000).
18. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini J. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102, 1503-1510 (2000).
19. Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 16(9 Pt 1), 715-718 (2003).
20. Orekhov AN, Tertov VV, Sobenin IA et al. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Intl J. Cardiol. 62(Suppl. 2), S67-S77 (1997).
21. Caduet®, package insert. Pfizer Ltd, NY, USA.
22. Frishman WH, Sica DA. Calcium channel blockers. In: Cardiovascular Pharmacotherapeutics Manual, Second Edition. Frishman WH, Sonnenblick EH, Sica DA (Eds), McGraw Hill NY, USA (2004).
23. Frishman WH, Cheng-Lai A, Nawarskas J. Current Cardiovascular Drugs, Fourth Edition. Current Medicine, PA, USA (2005) (In press).
24. Norvasc®, package insert. Pfizer Ltd, NY, USA.
25. Shachter NS, Frishman WH. Lipid-lowering drugs. In: Cardiovascular Pharmacotherapeutics Manual, Second Edition. Frishman WH, Sonnenblick EH, Sica DA (Eds), McGraw Hill, NY, USA (2004).
26. Frishman WH, Sica DA. Calcium-channel blockers. In: Cardiovascular Pharmacotherapeutics Manual, Second Edition. Frishman WH, Sonnenblick EH, Sica DA (Eds), McGraw Hill, NY, USA (2004)
27. Lipitor®, package insert. Pfizer Ltd, NY, USA.
28. Amlodipine/atorvastatin (Caduet®). Med. Lett. (2004) (In Press).
29. Frishman WH, Opie LH, Sica DA. Adverse cardiovascular drug interactions and complications. In: Hurst's the Heart, Eleventh Edition. Fuster V, Alexander RW, O'Rourke RA et al. (Eds), McGraw Hill, NY, USA (2004).
30. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT LLA): a multicenter, randomized, controlled trial. Lancet 361, 1149-1158 (2003).
31. Collaborative Atorvastatin Diabetes Study Group. Results from the Collaborative Atorvastatin Diabetes Study. 64th Scientific Sessions of the American Diabetes Association, Orlando, FL, USA, 6 June 2004.
32. ALLIANCE Trial Group. Results of the ALLIANCE trial. 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, 7-10 March 2004.
33. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet 362, 1527-1535 (2003).
34. Furburg CD, Wright JT, Davis BR et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J. Am. Med. Assoc. 288, 2981-2997 (2002).
35. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 36, 2022-2031 (2004).